132 related articles for article (PubMed ID: 10996830)
1. High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma.
Suguro M; Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
Am J Hematol; 2000 Oct; 65(2):132-5. PubMed ID: 10996830
[TBL] [Abstract][Full Text] [Related]
2. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM
J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690
[TBL] [Abstract][Full Text] [Related]
3. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma.
Barlogie B; Smallwood L; Smith T; Alexanian R
Ann Intern Med; 1989 Apr; 110(7):521-5. PubMed ID: 2647015
[TBL] [Abstract][Full Text] [Related]
4. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
5. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma.
Fosså A; Muer M; Kasper C; Welt A; Seeber S; Nowrousian MR
Leukemia; 1998 Mar; 12(3):422-6. PubMed ID: 9529138
[TBL] [Abstract][Full Text] [Related]
6. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
Mineur P; Ménard JF; Le Loët X; Bernard JF; Grosbois B; Pollet JP; Azais I; Laporte JP; Doyen C; De Gramont A; Wetterwald M; Euller-Ziegler L; Peny AM; Monconduit M; Michaux JL
Br J Haematol; 1998 Nov; 103(2):512-7. PubMed ID: 9827927
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ;
Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823
[TBL] [Abstract][Full Text] [Related]
8. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.
Gertz MA; Kalish LA; Kyle RA; Hahn RG; Tormey DC; Oken MM
Am J Clin Oncol; 1995 Dec; 18(6):475-80. PubMed ID: 8526187
[TBL] [Abstract][Full Text] [Related]
9. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
10. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
Friedenberg WR; Rue M; Blood EA; Dalton WS; Shustik C; Larson RA; Sonneveld P; Greipp PR
Cancer; 2006 Feb; 106(4):830-8. PubMed ID: 16419071
[TBL] [Abstract][Full Text] [Related]
12. Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features.
Niesvizky R; Siegel D; Glassman J; Straus D; Fine J; Lyons L; Michaeli J
Leuk Lymphoma; 2002 Mar; 43(3):607-12. PubMed ID: 12002766
[TBL] [Abstract][Full Text] [Related]
13. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Barlogie B; Velasquez WS; Alexanian R; Cabanillas F
J Clin Oncol; 1989 Oct; 7(10):1514-7. PubMed ID: 2778481
[TBL] [Abstract][Full Text] [Related]
14. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
15. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
Dimopoulos MA; Barlogie B; Smith TL; Alexanian R
Ann Intern Med; 1991 Dec; 115(12):931-5. PubMed ID: 1952489
[TBL] [Abstract][Full Text] [Related]
16. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen.
Stenzinger W; Blömker A; Hiddemann W; van de Loo J
Blut; 1990; 61(2-3):55-9. PubMed ID: 2207342
[TBL] [Abstract][Full Text] [Related]
18. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
[TBL] [Abstract][Full Text] [Related]
19. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
Delain M; Linassier C; Petitdidier C; Goupille P; Luthier F; Combe M; Reisenleiter M; Benboubker L; Lamagnère JP; Colombat P
J Clin Oncol; 1994 Dec; 12(12):2706-13. PubMed ID: 7989948
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
